The WEDZ Sci-Tech Innovation Investment Fund has announced its first investments by signing agreements and disbursing initial funds to Wuhan Inno Sensing Technology Co and Zhongmou Medical Technology Co.
This milestone marks a significant advancement in the operational phase of the Wuhan Economic & Technological Development Zone's (WEDZ) strategy to support early-stage, small-scale, and technology-driven enterprises through targeted financial backing.
The fund, characterized by its 12-year duration and 60 percent loss tolerance, is well-suited to meet the long-term development needs of technology companies.
Inno Sensing, founded in 2020, specializes in developing chips and hardware designs for products such as intelligent sensors and smart cockpits, tailored to new energy and connected vehicles. Its products are already in use by major domestic new energy vehicle brands, including Geely, Voyah, and Seres.
Zhongmou Medical, established by Professor Shen Yin of Wuhan University, focuses on its flagship product, ZM-02, a broad-spectrum optogenetic gene therapy drug. The financial support from the fund will enhance Zhongmou Medical's cash flow, facilitating global multi-center clinical trials of its core product and further pipeline development.
This initial investment underscores WEDZ's broader initiative to cultivate a robust tech-finance ecosystem. The fund aims to concentrate on emerging fields such as embodied intelligence, medical-engineering crossovers, precision manufacturing, and the low-altitude economy, driving innovation and growth in these cutting-edge sectors.
